scholarly journals P5-S7.03 Syphilis screening for high-risk groups in a large-scale HIV prevention program in India: uptake and trends

2011 ◽  
Vol 87 (Suppl 1) ◽  
pp. A343-A343
Author(s):  
M. Parthasarathy ◽  
N. Potty ◽  
A. Gurung ◽  
A. Das ◽  
P. Parimi
2013 ◽  
Vol 7 (06) ◽  
pp. 484-488 ◽  
Author(s):  
Mugundu Ramien Parthasarathy ◽  
Prakash Narayanan ◽  
Anjana Das ◽  
Anup Gurung ◽  
Parimi Prabhakar ◽  
...  

Introduction: Documented experiences from India on the implementation of syphilis screening in large-scale HIV prevention programs for “key populations at higher risk’ (KPs) are limited. Avahan is a large-scale HIV prevention program providing services to more than 300,000 KPs in six high HIV prevalence states of India since 2004. Avahan clinics provide a sexually transmitted infection service package which includes bi-annual syphilis screening. The trends in the coverage of syphilis screening among Avahan clinic attendees were studied retrospectively. Methodology: Screening was performed using either the Rapid Plasma Reagin (RPR) test or point-of-care immunochromatographic strip test (ICST). Clinic records from 2005 to 2009 were collated in an individual tracking database and analyzed with STATA-10. Results: Initially the coverage of syphilis screening (2.6% in 2005) was constrained by the availability and operational complexity of the RPR test. After its introduction in 2007, the use of ICST for screening increased from 7.4% to 77.0% and the proportion of clinic attendees screened increased from 9.0% to 21.6% during 2007-2009. The RPR reactivity rates declined from 6.6% (2006) to 4.4% (2009). Conclusion: The data showed improved rates of screening of clinic attendees and declining trends in sero-reactivity over time. The introduction of point-of-care syphilis tests may have contributed to the improved coverage of syphilis screening. The ICST may be considered for initial syphilis screening at other resource-constrained primary care sites in India such as ante-natal clinics and other KP interventions.


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jiayu He ◽  
Ying Wang ◽  
Zhicheng Du ◽  
Jing Liao ◽  
Na He ◽  
...  

2015 ◽  
Vol 105 (8) ◽  
pp. 664 ◽  
Author(s):  
Olive Shisana ◽  
Numpumelelo Zungu ◽  
Meredith Evans ◽  
Kathryn Risher ◽  
Thomas Rehle ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6037-6037
Author(s):  
William Allen Stokes ◽  
Laura H Hendrix ◽  
Trevor Joseph Royce ◽  
Ian M. Allen ◽  
Andrew Wang ◽  
...  

6037 Background: African-Americans (AA) are diagnosed with more advanced CaP than Caucasians (CA) and are more likely to die from CaP. Treatment delay is a potentially modifiable obstacle to care and clinically may be more important in AA patients because of more aggressive cancer at diagnosis. We examined time from diagnosis to curative treatment (surgery or radiation) in AA and CA patients in the Surveillance, Epidemiologic and End Results (SEER)-Medicare linked database. Methods: 21,454 CA and 2,506 AA patients who were diagnosed with non-metastatic CaP from 2004-08 and received treatment within 12 months of diagnosis were included. Linear regression was used to examine factors associated with number of days from diagnosis to treatment initiation, and logistic regression to assess odds of treatment within 6 months of diagnosis. Results: AA patients were more likely to have high-risk CaP than CA patients (39 vs. 35%), and less likely to have low-risk CaP (27 vs. 31%) (p<.001). Time to treatment was significantly prolonged for AA patients in all risk groups of CaP, and the difference was most prominent for high-risk patients (median 105 days for AA vs. 96 days for CA, p=.002). Racial differences in time to treatment persisted in multivariable analysis (Table). Sensitivity analyses examining the proportion of AA and CA patients initiating treatment within 6 months of diagnosis revealed similar results. Conclusions: AA patients, especially those with high-risk CaP, experience longer treatment delays than CA patients. This is the first large-scale study to examine treatment delays in AA and CA patients with CaP. The differences found may contribute to our understanding of racial disparities in CaP treatment outcomes. [Table: see text]


Addiction ◽  
2016 ◽  
Vol 111 (9) ◽  
pp. 1512-1515 ◽  
Author(s):  
Natasha K. Martin ◽  
Peter Vickerman ◽  
Matthew Hickman ◽  
Thomas L Patterson ◽  
Eleanor Rand ◽  
...  

2011 ◽  
Vol 87 (Suppl 1) ◽  
pp. A247-A248
Author(s):  
S. Chandrashekar ◽  
A. Vassall ◽  
B. Reddy ◽  
G. Shetty ◽  
M. Alary ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document